Alzheimer's disease biomarkers are crucial indicators used to detect and monitor the progression of Alzheimer's disease and dementia. These biomarkers include amyloid-beta and tau proteins, which accumulate abnormally in the brain, leading to cognitive decline and memory loss characteristic of the disease. Imaging techniques like PET scans can visualize amyloid plaques, while cerebrospinal fluid tests measure levels of amyloid-beta and tau proteins directly. Biomarkers play a pivotal role in early diagnosis, allowing for interventions to potentially slow disease progression and improve patient outcomes. Ongoing research focuses on refining these biomarkers to enhance accuracy and reliability in diagnosing Alzheimer's disease at its earliest stages, offering hope for better management and treatment strategies in the future.
Jun Hua
Johns Hopkins University , United States
Nazneen N Dewji
Cenna Biosciences Inc, United States
Jacqueline London
Paris Diderot University, FranceSubmit your abstract Today
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : Neuroimaging-based evaluation of scalp acupuncture for neural repair and reorganization in children with cerebral palsy
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : Neurophysiological change and cognitive response to levetiracetam in Alzheimer disease: Testing the missing mechanistic link
Christopher Hubler, Emergent Neural Systems Institute for Research, United States
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia